Goldman Sachs Group Inc Aeglea Bio Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	SELL	$0.11 - $0.46 $39,274 - $164,240	-357,045 Reduced 38.99%	558,650 $251,000
Q2 2023 Aug 14, 2023	BUY	$0.11 - $0.46 $61,451 - $256,979	558,650 New	558,650 $251,000
Q3 2022 May 14, 2024	SELL	$0.38 - $0.81 $103,207 - $219,994	-271,598 Reduced 22.88%	915,695 $482,000
Q3 2022 Nov 10, 2022	SELL	$0.38 - $0.81 $103,207 - $219,994	-271,598 Reduced 22.88%	915,695 $0
Q2 2022 May 14, 2024	BUY	$0.5 - $2.66 $593,646 - $3.16 Million	1,187,293 New	1,187,293 $600,000
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $31,252 - $166,260	62,504 Added 5.56%	1,187,293 $600,000
Q1 2022 May 16, 2022	SELL	$1.87 - $4.77 $17,880 - $45,610	-9,562 Reduced 0.84%	1,124,789 $2.59 Million
Q4 2021 Feb 14, 2022	SELL	$3.5 - $8.42 $5,946 - $14,305	-1,699 Reduced 0.15%	1,134,351 $5.39 Million
Q3 2021 Nov 10, 2021	BUY	$6.03 - $7.95 $6.85 Million - $9.03 Million	1,136,050 New	1,136,050 $9.03 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.